NO332038B1 - Beskyttelse, gjenoppbygging og styrking av erytropoietinresponsive celler, vev og organer. - Google Patents

Info

Publication number

NO332038B1

NO332038B1 NO20032912A NO20032912A NO332038B1 NO 332038 B1 NO332038 B1 NO 332038B1 NO 20032912 A NO20032912 A NO 20032912A NO 20032912 A NO20032912 A NO 20032912A NO 332038 B1 NO332038 B1 NO 332038B1

Authority

NO

Norway

Prior art keywords

erythropoietin

use according

modified

tissue

disease

Prior art date

2000-12-29

Links

• Espacenet
• Global Dossier
• Discuss

• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 619
• 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 536
• 229940105423 erythropoietin Drugs 0.000 title claims abstract description 531
• 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 530
• 210000000056 organ Anatomy 0.000 title claims abstract description 91
• 238000005728 strengthening Methods 0.000 title claims description 7
• 230000004224 protection Effects 0.000 title abstract description 15
• 230000000694 effects Effects 0.000 claims abstract description 41
• 241000124008 Mammalia Species 0.000 claims abstract description 27
• 230000035899 viability Effects 0.000 claims abstract description 20
• 210000004027 cell Anatomy 0.000 claims description 165
• 210000001519 tissue Anatomy 0.000 claims description 121
• 238000012986 modification Methods 0.000 claims description 75
• 230000004048 modification Effects 0.000 claims description 75
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
• 108010027485 asialoerythropoietin Proteins 0.000 claims description 41
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 31
• 125000003277 amino group Chemical group 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 28
• 210000004962 mammalian cell Anatomy 0.000 claims description 27
• 208000014674 injury Diseases 0.000 claims description 26
• 230000006378 damage Effects 0.000 claims description 25
• 238000011282 treatment Methods 0.000 claims description 25
• 238000004519 manufacturing process Methods 0.000 claims description 24
• 230000002829 reductive effect Effects 0.000 claims description 24
• 241000282414 Homo sapiens Species 0.000 claims description 23
• 230000006870 function Effects 0.000 claims description 22
• 125000005629 sialic acid group Chemical group 0.000 claims description 21
• 210000004556 brain Anatomy 0.000 claims description 20
• 210000002216 heart Anatomy 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 18
• 206010021143 Hypoxia Diseases 0.000 claims description 16
• 238000000338 in vitro Methods 0.000 claims description 16
• 230000003920 cognitive function Effects 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 15
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
• 239000004472 Lysine Substances 0.000 claims description 14
• 238000012360 testing method Methods 0.000 claims description 14
• 230000008733 trauma Effects 0.000 claims description 14
• 208000027418 Wounds and injury Diseases 0.000 claims description 13
• 229940079593 drug Drugs 0.000 claims description 13
• 208000028867 ischemia Diseases 0.000 claims description 13
• 206010015037 epilepsy Diseases 0.000 claims description 12
• 230000000913 erythropoietic effect Effects 0.000 claims description 12
• 210000003734 kidney Anatomy 0.000 claims description 12
• 230000002612 cardiopulmonary effect Effects 0.000 claims description 10
• 238000001727 in vivo Methods 0.000 claims description 10
• 230000002207 retinal effect Effects 0.000 claims description 10
• 241000238631 Hexapoda Species 0.000 claims description 9
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 9
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
• 210000003169 central nervous system Anatomy 0.000 claims description 9
• 230000001684 chronic effect Effects 0.000 claims description 9
• 230000001537 neural effect Effects 0.000 claims description 9
• 150000003839 salts Chemical class 0.000 claims description 9
• 208000010412 Glaucoma Diseases 0.000 claims description 8
• 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 8
• 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 8
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 8
• 210000004072 lung Anatomy 0.000 claims description 8
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 7
• 230000007954 hypoxia Effects 0.000 claims description 7
• 210000004185 liver Anatomy 0.000 claims description 7
• 210000001428 peripheral nervous system Anatomy 0.000 claims description 7
• 210000001550 testis Anatomy 0.000 claims description 7
• 208000001953 Hypotension Diseases 0.000 claims description 6
• 208000006011 Stroke Diseases 0.000 claims description 6
• 230000001154 acute effect Effects 0.000 claims description 6
• 210000004404 adrenal cortex Anatomy 0.000 claims description 6
• 210000001943 adrenal medulla Anatomy 0.000 claims description 6
• 230000002708 enhancing effect Effects 0.000 claims description 6
• 210000001672 ovary Anatomy 0.000 claims description 6
• 208000032253 retinal ischemia Diseases 0.000 claims description 6
• 210000000813 small intestine Anatomy 0.000 claims description 6
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 208000019901 Anxiety disease Diseases 0.000 claims description 5
• 206010012289 Dementia Diseases 0.000 claims description 5
• 241000282412 Homo Species 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 238000003556 assay Methods 0.000 claims description 5
• 208000010877 cognitive disease Diseases 0.000 claims description 5
• 230000003902 lesion Effects 0.000 claims description 5
• 210000003657 middle cerebral artery Anatomy 0.000 claims description 5
• 208000010496 Heart Arrest Diseases 0.000 claims description 4
• 208000013016 Hypoglycemia Diseases 0.000 claims description 4
• 208000019022 Mood disease Diseases 0.000 claims description 4
• 206010008129 cerebral palsy Diseases 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• 210000005168 endometrial cell Anatomy 0.000 claims description 4
• 208000002780 macular degeneration Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 210000004165 myocardium Anatomy 0.000 claims description 4
• 230000002669 organ and tissue protective effect Effects 0.000 claims description 4
• 210000000496 pancreas Anatomy 0.000 claims description 4
• 210000001525 retina Anatomy 0.000 claims description 4
• 238000002560 therapeutic procedure Methods 0.000 claims description 4
• 208000030507 AIDS Diseases 0.000 claims description 3
• 208000007848 Alcoholism Diseases 0.000 claims description 3
• 208000000044 Amnesia Diseases 0.000 claims description 3
• 206010002329 Aneurysm Diseases 0.000 claims description 3
• 206010003591 Ataxia Diseases 0.000 claims description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
• 206010003805 Autism Diseases 0.000 claims description 3
• 208000020706 Autistic disease Diseases 0.000 claims description 3
• 201000006474 Brain Ischemia Diseases 0.000 claims description 3
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
• 208000006136 Leigh Disease Diseases 0.000 claims description 3
• 208000024777 Prion disease Diseases 0.000 claims description 3
• 201000007930 alcohol dependence Diseases 0.000 claims description 3
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
• 208000029028 brain injury Diseases 0.000 claims description 3
• 210000001736 capillary Anatomy 0.000 claims description 3
• 230000002490 cerebral effect Effects 0.000 claims description 3
• 206010008118 cerebral infarction Diseases 0.000 claims description 3
• 210000004351 coronary vessel Anatomy 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• BFSYFTQDGRDJNV-AYHFEMFVSA-N fructosyllysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BFSYFTQDGRDJNV-AYHFEMFVSA-N 0.000 claims description 3
• 230000036543 hypotension Effects 0.000 claims description 3
• 230000006371 metabolic abnormality Effects 0.000 claims description 3
• 210000003205 muscle Anatomy 0.000 claims description 3
• 208000010125 myocardial infarction Diseases 0.000 claims description 3
• 230000004770 neurodegeneration Effects 0.000 claims description 3
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
• 230000000926 neurological effect Effects 0.000 claims description 3
• 230000000451 tissue damage Effects 0.000 claims description 3
• 231100000827 tissue damage Toxicity 0.000 claims description 3
• 230000002485 urinary effect Effects 0.000 claims description 3
• 208000031091 Amnestic disease Diseases 0.000 claims description 2
• 206010010904 Convulsion Diseases 0.000 claims description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 208000032843 Hemorrhage Diseases 0.000 claims description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
• 208000023105 Huntington disease Diseases 0.000 claims description 2
• 206010020772 Hypertension Diseases 0.000 claims description 2
• 208000017507 Leigh syndrome Diseases 0.000 claims description 2
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
• 201000002832 Lewy body dementia Diseases 0.000 claims description 2
• 206010026749 Mania Diseases 0.000 claims description 2
• 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
• 208000028389 Nerve injury Diseases 0.000 claims description 2
• 206010029350 Neurotoxicity Diseases 0.000 claims description 2
• 208000028017 Psychotic disease Diseases 0.000 claims description 2
• 206010038848 Retinal detachment Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
• 206010039966 Senile dementia Diseases 0.000 claims description 2
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
• 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
• 208000018839 Wilson disease Diseases 0.000 claims description 2
• 230000006986 amnesia Effects 0.000 claims description 2
• 230000036506 anxiety Effects 0.000 claims description 2
• 208000024732 dysthymic disease Diseases 0.000 claims description 2
• 230000003073 embolic effect Effects 0.000 claims description 2
• 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 2
• 208000037906 ischaemic injury Diseases 0.000 claims description 2
• 208000024714 major depressive disease Diseases 0.000 claims description 2
• 208000012268 mitochondrial disease Diseases 0.000 claims description 2
• 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
• 230000008764 nerve damage Effects 0.000 claims description 2
• 230000007135 neurotoxicity Effects 0.000 claims description 2
• 231100000228 neurotoxicity Toxicity 0.000 claims description 2
• 210000001328 optic nerve Anatomy 0.000 claims description 2
• 208000019906 panic disease Diseases 0.000 claims description 2
• 230000002980 postoperative effect Effects 0.000 claims description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
• 230000004264 retinal detachment Effects 0.000 claims description 2
• 208000022610 schizoaffective disease Diseases 0.000 claims description 2
• 201000000980 schizophrenia Diseases 0.000 claims description 2
• 210000003491 skin Anatomy 0.000 claims description 2
• 210000001508 eye Anatomy 0.000 claims 3
• 208000017194 Affective disease Diseases 0.000 claims 2
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
• NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 claims 2
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
• 208000024412 Friedreich ataxia Diseases 0.000 claims 1
• 208000013875 Heart injury Diseases 0.000 claims 1
• 206010061218 Inflammation Diseases 0.000 claims 1
• 206010027951 Mood swings Diseases 0.000 claims 1
• 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
• 208000031264 Nerve root compression Diseases 0.000 claims 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
• 208000026301 Postoperative Cognitive Complications Diseases 0.000 claims 1
• 208000019155 Radiation injury Diseases 0.000 claims 1
• 206010037779 Radiculopathy Diseases 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 claims 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
• 208000002667 Subdural Hematoma Diseases 0.000 claims 1
• 208000016620 Tourette disease Diseases 0.000 claims 1
• 201000011040 acute kidney failure Diseases 0.000 claims 1
• 208000012998 acute renal failure Diseases 0.000 claims 1
• 206010063452 arteriosclerotic retinopathy Diseases 0.000 claims 1
• 210000000988 bone and bone Anatomy 0.000 claims 1
• 210000002449 bone cell Anatomy 0.000 claims 1
• 230000006931 brain damage Effects 0.000 claims 1
• 231100000874 brain damage Toxicity 0.000 claims 1
• 230000000747 cardiac effect Effects 0.000 claims 1
• 210000000748 cardiovascular system Anatomy 0.000 claims 1
• 210000001627 cerebral artery Anatomy 0.000 claims 1
• 230000007547 defect Effects 0.000 claims 1
• 210000000750 endocrine system Anatomy 0.000 claims 1
• 210000003038 endothelium Anatomy 0.000 claims 1
• 210000003754 fetus Anatomy 0.000 claims 1
• 210000005095 gastrointestinal system Anatomy 0.000 claims 1
• 208000006454 hepatitis Diseases 0.000 claims 1
• 231100000283 hepatitis Toxicity 0.000 claims 1
• 210000000987 immune system Anatomy 0.000 claims 1
• 230000004054 inflammatory process Effects 0.000 claims 1
• 210000001161 mammalian embryo Anatomy 0.000 claims 1
• 201000006938 muscular dystrophy Diseases 0.000 claims 1
• 230000002107 myocardial effect Effects 0.000 claims 1
• 230000003557 neuropsychological effect Effects 0.000 claims 1
• 210000004994 reproductive system Anatomy 0.000 claims 1
• 210000002345 respiratory system Anatomy 0.000 claims 1
• 210000001927 retinal artery Anatomy 0.000 claims 1
• 210000001957 retinal vein Anatomy 0.000 claims 1
• 210000004927 skin cell Anatomy 0.000 claims 1
• 208000020431 spinal cord injury Diseases 0.000 claims 1
• 208000023516 stroke disease Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 47
• 239000000203 mixture Substances 0.000 abstract description 42
• -1 erythropoietin modified erythropoietin Chemical class 0.000 abstract description 28
• 108010075944 Erythropoietin Receptors Proteins 0.000 abstract description 23
• 102100036509 Erythropoietin receptor Human genes 0.000 abstract description 23
• 230000009885 systemic effect Effects 0.000 abstract description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 44
• 150000001720 carbohydrates Chemical class 0.000 description 42
• 238000006243 chemical reaction Methods 0.000 description 40
• 230000004888 barrier function Effects 0.000 description 39
• 235000014633 carbohydrates Nutrition 0.000 description 39
• 239000000243 solution Substances 0.000 description 26
• 235000001014 amino acid Nutrition 0.000 description 25
• 229940024606 amino acid Drugs 0.000 description 24
• 150000001413 amino acids Chemical class 0.000 description 24
• 210000002889 endothelial cell Anatomy 0.000 description 22
• 241001465754 Metazoa Species 0.000 description 20
• 108090000623 proteins and genes Proteins 0.000 description 20
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
• 230000013595 glycosylation Effects 0.000 description 18
• 238000006206 glycosylation reaction Methods 0.000 description 18
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 18
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 17
• 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 17
• 102000044890 human EPO Human genes 0.000 description 17
• 235000002639 sodium chloride Nutrition 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
• 230000014509 gene expression Effects 0.000 description 16
• 239000000047 product Substances 0.000 description 15
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 14
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 14
• 230000027455 binding Effects 0.000 description 14
• 238000001356 surgical procedure Methods 0.000 description 14
• LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical group O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 13
• 230000010412 perfusion Effects 0.000 description 13
• 210000005166 vasculature Anatomy 0.000 description 13
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
• 238000011065 in-situ storage Methods 0.000 description 12
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 125000000524 functional group Chemical group 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 238000006722 reduction reaction Methods 0.000 description 11
• 239000011780 sodium chloride Substances 0.000 description 11
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 10
• 230000037396 body weight Effects 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 102000004169 proteins and genes Human genes 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 235000000346 sugar Nutrition 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• 239000000556 agonist Substances 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 125000003396 thiol group Chemical group [H]S* 0.000 description 9
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 9
• 241000196324 Embryophyta Species 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• 108090000141 Sialyltransferases Proteins 0.000 description 8
• 229960002685 biotin Drugs 0.000 description 8
• 235000020958 biotin Nutrition 0.000 description 8
• 239000011616 biotin Substances 0.000 description 8
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 8
• 230000001146 hypoxic effect Effects 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 230000000670 limiting effect Effects 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 238000003860 storage Methods 0.000 description 7
• 230000032258 transport Effects 0.000 description 7
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
• 235000002374 tyrosine Nutrition 0.000 description 7
• 239000004475 Arginine Substances 0.000 description 6
• 239000004971 Cross linker Substances 0.000 description 6
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
• 102000003838 Sialyltransferases Human genes 0.000 description 6
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
• 125000003275 alpha amino acid group Chemical group 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 230000003915 cell function Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 229940015043 glyoxal Drugs 0.000 description 6
• 229940088597 hormone Drugs 0.000 description 6
• 239000005556 hormone Substances 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 238000011321 prophylaxis Methods 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 230000031998 transcytosis Effects 0.000 description 6
• 238000002054 transplantation Methods 0.000 description 6
• 230000002861 ventricular Effects 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 235000003704 aspartic acid Nutrition 0.000 description 5
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 238000013270 controlled release Methods 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 238000000502 dialysis Methods 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 230000010437 erythropoiesis Effects 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 5
• 239000000122 growth hormone Substances 0.000 description 5
• 210000002569 neuron Anatomy 0.000 description 5
• 238000007911 parenteral administration Methods 0.000 description 5
• 230000017854 proteolysis Effects 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 4
• UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 108010051696 Growth Hormone Proteins 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• 108090001061 Insulin Proteins 0.000 description 4
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
• 102000005348 Neuraminidase Human genes 0.000 description 4
• 108010006232 Neuraminidase Proteins 0.000 description 4
• 241000276498 Pollachius virens Species 0.000 description 4
• 102100038803 Somatotropin Human genes 0.000 description 4
• 229940088710 antibiotic agent Drugs 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 230000008499 blood brain barrier function Effects 0.000 description 4
• 210000001218 blood-brain barrier Anatomy 0.000 description 4
• 150000007942 carboxylates Chemical group 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 210000003989 endothelium vascular Anatomy 0.000 description 4
• 125000004185 ester group Chemical group 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000002523 gelfiltration Methods 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 244000144972 livestock Species 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 230000003818 metabolic dysfunction Effects 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 238000006396 nitration reaction Methods 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000008092 positive effect Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 239000003053 toxin Substances 0.000 description 4
• 231100000765 toxin Toxicity 0.000 description 4
• 108700012359 toxins Proteins 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003497 Asphyxia Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 3
• 208000005374 Poisoning Diseases 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 3
• 102000009618 Transforming Growth Factors Human genes 0.000 description 3
• 108010009583 Transforming Growth Factors Proteins 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 230000021736 acetylation Effects 0.000 description 3
• 238000006640 acetylation reaction Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 3
• 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 3
• 150000001510 aspartic acids Chemical class 0.000 description 3
• 238000003287 bathing Methods 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 210000002937 blood-testis barrier Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000021235 carbamoylation Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 239000003431 cross linking reagent Substances 0.000 description 3
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000035487 diastolic blood pressure Effects 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 150000002148 esters Chemical group 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 230000026045 iodination Effects 0.000 description 3
• 238000006192 iodination reaction Methods 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 239000012948 isocyanate Substances 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000012280 lithium aluminium hydride Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 230000003387 muscular Effects 0.000 description 3
• 210000000944 nerve tissue Anatomy 0.000 description 3
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 231100000572 poisoning Toxicity 0.000 description 3
• 230000000607 poisoning effect Effects 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000010410 reperfusion Effects 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 229940014800 succinic anhydride Drugs 0.000 description 3
• 230000035322 succinylation Effects 0.000 description 3
• 238000010613 succinylation reaction Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 238000002689 xenotransplantation Methods 0.000 description 3
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
• 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010002199 Anaphylactic shock Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
• 201000006306 Cor pulmonale Diseases 0.000 description 2
• 108010074604 Epoetin Alfa Proteins 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 108010076876 Keratins Proteins 0.000 description 2
• 102000011782 Keratins Human genes 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 208000006079 Near drowning Diseases 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 206010060860 Neurological symptom Diseases 0.000 description 2
• 101710138657 Neurotoxin Proteins 0.000 description 2
• XCCHFTFMUQWCPL-GXQDVZPWSA-N ON1C(CCC1=O)=O.C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)C(C(=O)O)CCCCN Chemical class ON1C(CCC1=O)=O.C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)C(C(=O)O)CCCCN XCCHFTFMUQWCPL-GXQDVZPWSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
• 206010037180 Psychiatric symptoms Diseases 0.000 description 2
• 241000442474 Pulsatilla vulgaris Species 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 208000004891 Shellfish Poisoning Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 208000009979 Traumatic Amputation Diseases 0.000 description 2
• 206010053648 Vascular occlusion Diseases 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000003172 aldehyde group Chemical group 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 102000005936 beta-Galactosidase Human genes 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
• JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 108700001003 carbamylated erythropoietin Proteins 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 230000005779 cell damage Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 108010004031 deoxyribonuclease A Proteins 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 125000005594 diketone group Chemical group 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 150000002019 disulfides Chemical class 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• VZFRNCSOCOPNDB-AJKFJWDBSA-N domoic acid Chemical compound OC(=O)[C@@H](C)\C=C\C=C(/C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AJKFJWDBSA-N 0.000 description 2
• VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000012039 electrophile Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 210000004696 endometrium Anatomy 0.000 description 2
• 230000008497 endothelial barrier function Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000004997 halocarbonyl group Chemical group 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000002218 hypoglycaemic effect Effects 0.000 description 2
• 208000021822 hypotensive Diseases 0.000 description 2
• 230000001077 hypotensive effect Effects 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 206010022498 insulinoma Diseases 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
• VZFRNCSOCOPNDB-OXYNIABMSA-N isodomoic acid D Natural products CC(C=C/C=C(/C)C1CNC(C1CC(=O)O)C(=O)O)C(=O)O VZFRNCSOCOPNDB-OXYNIABMSA-N 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 230000003961 neuronal insult Effects 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• 239000002581 neurotoxin Substances 0.000 description 2
• 231100000618 neurotoxin Toxicity 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000004768 organ dysfunction Effects 0.000 description 2
• 210000003300 oropharynx Anatomy 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 208000021255 pancreatic insulinoma Diseases 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 238000004321 preservation Methods 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000000541 pulsatile effect Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 208000017443 reproductive system disease Diseases 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 235000004400 serine Nutrition 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 210000001578 tight junction Anatomy 0.000 description 2
• 230000009092 tissue dysfunction Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 208000014001 urinary system disease Diseases 0.000 description 2
• 208000021331 vascular occlusion disease Diseases 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
• GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• ZZYYVZYAZCMNPG-MLWJPKLSSA-N (2s)-6-amino-2-(1-carboxyethylamino)hexanoic acid Chemical compound OC(=O)C(C)N[C@H](C(O)=O)CCCCN ZZYYVZYAZCMNPG-MLWJPKLSSA-N 0.000 description 1
• RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-M 2,4,6-trinitrobenzenesulfonate Chemical group [O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NHJVRSWLHSJWIN-UHFFFAOYSA-M 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical group C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
• QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical class O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
• LBYBJJOUISDNRJ-UHFFFAOYSA-N 4-isothiocyanatobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(N=C=S)C=C1 LBYBJJOUISDNRJ-UHFFFAOYSA-N 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
• 206010060933 Adverse event Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 241000239223 Arachnida Species 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 102100033787 CMP-sialic acid transporter Human genes 0.000 description 1
• 101710150575 CMP-sialic acid transporter Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
• 102000003670 Carboxypeptidase B Human genes 0.000 description 1
• 108090000087 Carboxypeptidase B Proteins 0.000 description 1
• 102000000496 Carboxypeptidases A Human genes 0.000 description 1
• 108010080937 Carboxypeptidases A Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 108700027941 Celsior Proteins 0.000 description 1
• 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
• QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108010038061 Chymotrypsinogen Proteins 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010011086 Coronary artery occlusion Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 230000010777 Disulfide Reduction Effects 0.000 description 1
• 208000003870 Drug Overdose Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
• 102100031939 Erythropoietin Human genes 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 206010056438 Growth hormone deficiency Diseases 0.000 description 1
• 102000015779 HDL Lipoproteins Human genes 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 208000004619 Inert Gas Narcosis Diseases 0.000 description 1
• 208000009773 Insulin Coma Diseases 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 238000012347 Morris Water Maze Methods 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 206010033296 Overdoses Diseases 0.000 description 1
• 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
• 206010056332 Panencephalitis Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
• 201000007527 Retinal artery occlusion Diseases 0.000 description 1
• 206010040576 Shock hypoglycaemic Diseases 0.000 description 1
• 101710165315 Sialidase A Proteins 0.000 description 1
• 108050000175 Sialidase-2 Proteins 0.000 description 1
• 102100028755 Sialidase-2 Human genes 0.000 description 1
• 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 1
• 208000012931 Urologic disease Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 210000002159 anterior chamber Anatomy 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 150000001483 arginine derivatives Chemical class 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 229940090047 auto-injector Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000007177 brain activity Effects 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 201000008191 cerebritis Diseases 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000006328 chemical modification of amino acids Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 210000003703 cisterna magna Anatomy 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
• 238000007333 cyanation reaction Methods 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000002243 cyclohexanonyl group Chemical group *C1(*)C(=O)C(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 231100000725 drug overdose Toxicity 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 208000002296 eclampsia Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000002571 electroretinography Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229940089118 epogen Drugs 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000003209 gene knockout Methods 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229940050526 hydroxyethylstarch Drugs 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940076264 interleukin-3 Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 235000014413 iron hydroxide Nutrition 0.000 description 1
• NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 210000005240 left ventricle Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 208000012866 low blood pressure Diseases 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 239000001755 magnesium gluconate Substances 0.000 description 1
• 229960003035 magnesium gluconate Drugs 0.000 description 1
• 235000015778 magnesium gluconate Nutrition 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000006677 mitochondrial metabolism Effects 0.000 description 1
• ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000007512 neuronal protection Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 231100001223 noncarcinogenic Toxicity 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 238000006213 oxygenation reaction Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000008014 pharmaceutical binder Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical group [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000001292 preischemic effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 229940029359 procrit Drugs 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 229940121896 radiopharmaceutical Drugs 0.000 description 1
• 230000002799 radiopharmaceutical effect Effects 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 229940075993 receptor modulator Drugs 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004243 retinal function Effects 0.000 description 1
• 208000004644 retinal vein occlusion Diseases 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 208000037921 secondary disease Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 239000002884 skin cream Substances 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 239000000176 sodium gluconate Substances 0.000 description 1
• 235000012207 sodium gluconate Nutrition 0.000 description 1
• 229940005574 sodium gluconate Drugs 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000010009 steroidogenesis Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000008054 sulfonate salts Chemical class 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 229910052717 sulfur Chemical group 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940100611 topical cream Drugs 0.000 description 1
• 229940100615 topical ointment Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1